A detailed history of Macquarie Group LTD transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Macquarie Group LTD holds 887,275 shares of LGND stock, worth $101 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
887,275
Previous 966,552 8.2%
Holding current value
$101 Million
Previous $81.4 Million 9.13%
% of portfolio
0.1%
Previous 0.1%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$82.7 - $110.11 $6.56 Million - $8.73 Million
-79,277 Reduced 8.2%
887,275 $88.9 Million
Q2 2024

Aug 09, 2024

SELL
$68.53 - $87.91 $4.57 Million - $5.86 Million
-66,629 Reduced 6.45%
966,552 $81.4 Million
Q1 2024

May 14, 2024

BUY
$68.64 - $89.2 $3.15 Million - $4.09 Million
45,827 Added 4.64%
1,033,181 $75.5 Million
Q4 2023

Feb 14, 2024

SELL
$49.57 - $72.63 $221,280 - $324,220
-4,464 Reduced 0.45%
987,354 $70.5 Million
Q3 2023

Nov 14, 2023

BUY
$58.86 - $72.67 $9.1 Million - $11.2 Million
154,648 Added 18.47%
991,818 $59.4 Million
Q2 2023

Aug 14, 2023

BUY
$69.53 - $79.33 $1.33 Million - $1.52 Million
19,187 Added 2.35%
837,170 $60.4 Million
Q1 2023

May 15, 2023

BUY
$65.67 - $77.08 $1.14 Million - $1.34 Million
17,387 Added 2.17%
817,983 $60.2 Million
Q4 2022

Feb 21, 2023

BUY
$61.72 - $96.74 $430,497 - $674,761
6,975 Added 0.88%
800,596 $53.5 Million
Q3 2022

Nov 14, 2022

BUY
$0.01 - $107.56 $96 - $1.04 Million
9,697 Added 1.24%
793,621 $68.3 Million
Q2 2022

Aug 15, 2022

BUY
$74.52 - $117.06 $1.88 Million - $2.95 Million
25,183 Added 3.32%
783,924 $69.9 Million
Q1 2022

May 16, 2022

BUY
$94.99 - $151.56 $12.7 Million - $20.3 Million
133,772 Added 21.4%
758,741 $85.4 Million
Q4 2021

Feb 11, 2022

SELL
$127.69 - $165.85 $2.53 Million - $3.29 Million
-19,809 Reduced 3.07%
624,969 $96.5 Million
Q3 2021

Nov 12, 2021

BUY
$102.33 - $144.73 $5.23 Million - $7.39 Million
51,080 Added 8.6%
644,778 $89.8 Million
Q2 2021

Aug 13, 2021

BUY
$113.03 - $155.64 $12.4 Million - $17 Million
109,340 Added 22.57%
593,698 $77.9 Million
Q1 2021

May 14, 2021

SELL
$99.52 - $215.83 $40.8 Million - $88.6 Million
-410,320 Reduced 45.86%
484,358 $73.8 Million
Q4 2020

Feb 16, 2021

BUY
$80.55 - $106.05 $11.2 Million - $14.7 Million
138,545 Added 18.32%
894,678 $89 Million
Q3 2020

Nov 13, 2020

BUY
$89.56 - $126.72 $1.26 Million - $1.78 Million
14,080 Added 1.9%
756,133 $72.1 Million
Q2 2020

Aug 11, 2020

BUY
$68.28 - $123.65 $3.34 Million - $6.05 Million
48,968 Added 7.07%
742,053 $83 Million
Q1 2020

May 15, 2020

BUY
$63.37 - $107.88 $3.41 Million - $5.81 Million
53,820 Added 8.42%
693,085 $50.4 Million
Q4 2019

Feb 14, 2020

BUY
$96.94 - $113.59 $7.69 Million - $9.01 Million
79,300 Added 14.16%
639,265 $66.7 Million
Q3 2019

Nov 14, 2019

BUY
$86.25 - $120.16 $2.94 Million - $4.1 Million
34,128 Added 6.49%
559,965 $55.7 Million
Q2 2019

Aug 14, 2019

BUY
$107.38 - $129.34 $3.76 Million - $4.53 Million
35,055 Added 7.14%
525,837 $60 Million
Q1 2019

May 15, 2019

BUY
$105.93 - $142.47 $5.42 Million - $7.29 Million
51,195 Added 11.65%
490,782 $61.7 Million
Q4 2018

Feb 15, 2019

BUY
$128.36 - $272.13 $8.43 Million - $17.9 Million
65,712 Added 17.58%
439,587 $59.7 Million
Q3 2018

Nov 15, 2018

SELL
$211.18 - $274.49 $4.91 Million - $6.38 Million
-23,238 Reduced 5.85%
373,875 $103 Million
Q2 2018

Aug 14, 2018

BUY
$150.77 - $207.98 $1.5 Million - $2.07 Million
9,970 Added 2.58%
397,113 $82.3 Million
Q1 2018

May 11, 2018

BUY
$138.63 - $182.62 $2.55 Million - $3.36 Million
18,420 Added 5.0%
387,143 $63.9 Million
Q4 2017

Feb 15, 2018

SELL
$128.36 - $147.04 $12.1 Million - $13.9 Million
-94,312 Reduced 20.37%
368,723 $50.5 Million
Q3 2017

Nov 08, 2017

BUY
$120.91 - $137.94 $56 Million - $63.9 Million
463,035
463,035 $63 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.91B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Macquarie Group LTD Portfolio

Follow Macquarie Group LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.